Skip to main content

Clinical characteristics and risk factors of ovarian reserve decreases in women with Crohn’s disease: a case-control study



Crohn’s disease (CD), often occurring in women of child-bearing age, can decline the fertility rate. However, whether it reduces ovarian reserve has been rarely reported. This study aimed to evaluate the ovarian reserve in women with CD from the perspective of anti-Müllerian hormone (AMH), and explore the factors that can decrease ovarian reserve.


A case-control retrospective study was designed. We analyzed the AMH levels in a total of 135 CD women and 878 healthy controls. Through propensity score matching, the subjects were assigned in a ratio of 1:3 to CD group (n = 121) and control group (n = 324). Both groups shared similar basic characteristics, like age, body mass index and smoking status. Serum AMH levels were measured by chemiluminescence.


The AMH level in the CD group was significantly lower than that in the control group (2.17 ± 2.23 μg/L vs 3.95 ± 2.01 μg/L, 95%CI [1.34-2.21], P < 0.001). In both groups, the AMH levels decreased as age increased, but without between-group difference in the decreasing rate (P = 0.639). Multivariate analysis showed that age > 30 years (OR, 2.905; 95%CI [1.053-8.531], P = 0.017), disease activity (OR,4.314; 95%CI [1.561-12.910], P = 0.002) and thalidomide use (OR,12.628; 95%CI [4.351 -42.820], P < 0.001) were independent risk factors associated with decreased ovarian reserve (AMH<1.1μg/L).


Ovarian reserve is lower in CD women than in healthy women. Age, CD activity and medication of thalidomide are risk factors that can aggravate the decline of ovarian reserve.


Crohn’s disease (CD), a chronic non-specific inflammatory bowel disease, often sets on in women aged 20-35 years, a high time of child-bearing [1]. CD may exert negative effects on women’s fertility and pregnancy [2]. It has reported that the fertility of CD women declines, meanwhile the risk of infertility rises [3]. Multiple factors contribute to fertility decline in CD women. (1) Inflammatory response poses deleterious effects on the function of organs in the pelvic cavity. For example, salpingitis, ovaritis and pelvic surgery may cause infertility, and medication in treating these diseases may also damage ovarian function [4, 5]. (2) CD activity, surgery, pain and sexual dysfunction can lead to sexual inactivity and subsequent infertility [6]. (3) CD women may refuse fertility for fear of the heritability of CD, or the negative effects of CD on pregnancy and fetus [7]. About 14-18% of CD women initiatively give up pregnancy, with a proportion significantly higher than the 6% in healthy women [8, 9]. (4) CD women may experience psychological disorders, like anxiety and depression, with a high incidence doubling that in the healthy population. These disorders further impair sexual function and consequent fertility. These four aspects can explain the high infertility rate in CD women [10].

The pregnancy and fertility of CD women can be indirectly evaluated through pregnancy outcomes, such as the number of infants or the delay of fertilization in the married women. In addition, some research findings are contradictory. In fact, infertility is sometimes a result of initiative selection or national policy. Pregnancy outcomes cannot offer an objective reflection on the fertility and ovarian reserve in CD women.

Ovarian reserve, judged by the number and quality of follicles remaining in the ovary, can be used to provide reliable information about female fertility. As the ovarian reserve decreases, the ability of the ovary to produce oocytes and the quality of follicles fall, probably followed by infertility. Ovarian reserve can be estimated through various hormones, such as follicle stimulating hormone (FSH), estradiol (E2), luteinizing hormone (LH) and inhibin B [11]. However, the efficiency of these indexes is always restricted. Anti-Müllerian hormone (AMH) is released by preantral or antral follicles. In the peripheral blood, AMH is the follicle-released substance that can be first detected. The level of AMH fluctuates slightly during the menstrual cycle, making it successfully detected at any time point. Compared to other hormones, AMH is more convenient and accurate in evaluating ovarian reserve [12]. Low AMH can predict decreased ovarian reserve. As usual, an AMH level < 1.1μg/L indicates a low ovarian reserve [13, 14].

In this study, we retrospectively analyzed the AMH levels in CD women and healthy control, aiming to find out CD-related factors affecting ovarian reserve.

Materials and methods

Design and subjects

A retrospective analysis was designed. Recruited were patients treated for CD at the Inflammatory Bowel Disease Center of the Sixth Affiliated Hospital, Sun Yat-sen University from July 2017 to December 2021. This case-control study was approved by the Ethics Committee of the Sixth Affiliated Hospital, Sun Yat-sen University (2017ZSLYEC-077). Inclusion criteria: (1) women aged 20-40 years. (2) CD diagnosed within previous 6 months according to medical history, endoscopic, imaging and pathological features, and European Crohn’s and Colitis Organization (ECCO) consensus guidelines.

Data of healthy and aged-matched controls were collected from demographic bank of the Reproductive Medicine Center at our hospital. The database was established by the hospital for the epidemiological survey of ovarian function in women of reproductive age. The control were selected from women without known diseases and who had never received any drug. In addition, women must have no Crohn’s disease.

Exclusion criteria for two groups included: (1) previous surgery of ovaries; (2) polycystic ovarian syndrome; (3) history of ovarian cancer; (4) endocrine and metabolic diseases; (5) hepatic, renal and cardiac dysfunction; (6) previous use of cytotoxic drugs; (7) history of pelvic radiotherapy; (8) oral contraceptives; (9) history of malignant tumors. This study was approved by the Ethics Committee of the Sixth Affiliated Hospital, Sun Yat-sen University. All subjects provided written informed consent.


Data about age, height, weight, body mass index (BMI), smoking, disease duration, location, disease behavior, previous medical therapies, C-reactive protein (CRP), hemoglobin, albumin and AMH were collected from medical records or demographic bank of the Center. The serum AMH level detection methods for the both groups were consistent. The samples were detected with automatic chemiluminescence method in the same center using the kit from the same company (AMH Immunotech S.A.S a Beckman Coulter Company, France).

Statistical analysis

All analyses were performed on SPSS 22.0. According to the technique of propensity score matching, the basic data were matched in a ratio of 1:3. Common statistical tests included Kolmogorov-Smirnov test (KS test) and Shapiro-Wilk test (SW test). When the p value of test results was less than 0.05, we considered that the data were not in the normal distribution. Continuous variables were expressed as mean ± standard deviation. The nonpaired data in normal distribution were analyzed by t test, otherwise by Wilcoxon2-sample test. Categorical variables were expressed as absolute value and percentage, and subjected to Fisher’s exact test or Yates’ chi-square test. One-way analysis of variance was performed for screening risk factors. Those with p < 0.2 were submitted to binary logistic regression analysis. All analyses were two-tailed and P < 0.05 was considered as statistically significant.


Basic data

A total of 135 CD women and 878 healthy women were enrolled. After propensity score matching, 121 CD women were assigned to the Crohn’s group and 324 healthy women to the control group, with similar age, BMI and smoking status (Table 1).

Table 1 Age, BMI Score, Smoker Status in Crohn’s and Control Group

AMH levels in two groups

The AMH level in the CD group was significantly lower than that in the control group (2.17 ± 2.23 μg/L vs 3.95 ± 2.01 μg/L, 95%CI [1.34 to 2.21], P < 0.001) (Fig. 1A). The proportion of women with decreased ovarian reserve (AMH ≤ 1.1μg/L) was higher than that in the control group (42.15% vs 0%, p < 0.001) (Fig. 1B).

Fig. 1
figure 1

Comparison of AMH between CD patients and control

Association between AMH and age

In both groups, the AMH level decreased as age increased. The slope of the regression line was − 0.11 in the CD group and − 0.13 in the control group, without statistical difference (P = 0.639) (Fig. 2).

Fig. 2
figure 2

Relationship between AMH and age in CD and control group

Factors affecting ovarian reserve

In the CD group, 51 (42.15%) of patients presented decreased ovarian reserve. As found in analyses of age, disease activity, behavior and medication history, the decreased ovarian reserve was associated with age > 30 years (OR, 2.036; 95%CI[0.957-4.464], P = 0.066), disease activity (OR, 3.795; 95%CI[1.785-7.951], P < 0.001), penetrating lesion (OR, 1.952; 95%CI[0.813-4.392], P = 0.127), anemia (Hg ≤ 110 g/L) (OR, 1.704; 95%CI[0.840-3.508], P = 0.156), steroids (OR, 2.191; 95%CI[1.029-4.558], P = 0.035), azathioprine (OR, 1.888; 5%CI[0.885-3.935;], P = 0.089), thalidomide (OR, 7.333; 95%CI[3.268-17.141],P < 0.001), infliximab (OR, 1.852; 95%CI[0.933-3.818], P = 0.113) (Fig. 3A). Variables with P < 0.2 were included in the binary logistic regression analysis. We found that age > 30 years (OR, 2.905; 95%CI[1.053-8.531], P = 0.017), disease activity (OR, 4.314; 95%CI[1.561-12.910], P = 0.002), and thalidomide use (OR, 12.628; 95%CI[4.351-42.380], P < 0.001) were independent risk factors for decreased ovarian reserve (Fig. 3B).

Fig. 3
figure 3

Risk factors associated with decreased ovarian reserve


CD often sets on in a child-bearing age [1]. It remains a controversy whether CD impairs fertility of women. Studies have shown a lower fertility rate in CD women than in the healthy [15]. In our study, the number of children in the CD group were lower than the control group, and the miscarriage rate was higher, but no significant difference was found. It may be related to several factors. For example, some of the women with Crohn’s disease have had children before diagnosis, some may have a delayed fertilization plan, or some may be unwilling to be fertilized. Besides, the disease activity, medication history and surgery may also influence the fertility rate. Meanwhile, as the fertilization delays, the ovarian reserve declines. In addition, CD may also involve the ovarian ducts and the ovaries, the inflammation of which also damages female fertility [16, 17]. However, changes in fertility rate of patients could not fully represent the true ovarian reserve function. Therefore, it is a clinical urgency to define the association of CD with female fertility, as well as the risk factors of fertile failure [18, 19]. This information can help CD women to design an optimal strategy for pregnancy.

A lower AMH level predicts a poorer ovarian reserve or a weaker response to ovarian stimulation. A study has verified the accuracy of AMH in predicting the ovarian reserve in females with lupus erythematosus, indicating that AMH can be used to evaluate the toxicity in sexual glands. Therefore, AMH was introduced into the present study to judge the ovarian reserve and potential fertility of females with CD.

In this study, the AMH level in CD women was significantly lower than that in the healthy (2.17 ± 2.23μg/L vs 3.95 ± 2.01μg/L; 95%CI [1.34 to 2.21], P < 0.001), so was the incidence of decreased ovarian reserve (AMH ≤ 1.1 μg/L) (42.15% vs 0%, P < 0.001). These findings verify that the ovarian reserve declines in CD women, thus explaining why CD women show a lower fertility rate than the healthy [17, 20].

Ovarian reserve falls as age increases, which is also proven in the present study. In both groups, the AMH levels decreased with age, but their decreasing rate showed no significant between-group difference. Subgroup analysis further demonstrated that age > 30 years (OR, 2.905; 95%CI [1.053-8.531], P = 0.017) was an independent risk factor of decreased ovarian reserve in CD women, a finding that supports the profile of AMH in these patients. Freour [21] et al. reported that AMH levels were significantly lower in CD women under 30 years old, but remained comparable in those over 30 years old. This difference may be attributed to the fact that their study only chose the patients with quiescent disease, and an IVF population with a normal ovarian reserve status as the control group, who can be considered different from the general population. For CD patients who delay their ferritization plan or those who are unwilling to be fertilized, they may worry about the impacts of disease activity, medication history, and surgery on their fertility. Therefore, for CD women aged over 30 years and refusing fertilization, health education should be carried out to alleviate their anxiety about disease heritability and adverse pregnancy outcomes.

During the development of CD, pro-inflammatory factors are released into the blood, then penetrate the bowel wall, and trigger peritoneal inflammation that may further involve the ovaries. This pathology, though having not led to reproductive organic damage, may still decline fertility. Winger has found that the use of TNF-alpha inhibitors and intravenous immunoglobulin (IVIG) significantly improves in vitro fertilization (IVF) outcome in young infertile women withTh1/Th2 cytokine elevation [22]. In a study including 35 CD women, the AMH level is inversely associated with the score of Crohn’s Disease Activity Index (CDAI) [23]. In the present study, we found a consistent result that disease activity (OR, 4.314; 95%CI[1.561-12.910], P = 0.002) is an independent risk factor of decreased ovarian reserve. It has also proven that the risk of adverse pregnancy is higher in the active phase than in the remitting phase [20, 24]. Therefore, accelerating the disease into the remitting phase can reduce the damage to ovarian reserve and increase the odds of successful fertilization.

Some drugs have been suspected to have negative effects on ovarian reserve. In the present study, we reviewed the history of medication in CD women. Multivariate analysis discovered use of thalidomide (OR,12.628; 95%CI[4.351-42.380]; P < 0.001) as an independent risk factor for decreased ovarian reserve, which is consistent with our previous finding that thalidomide exerts negative effects on ovarian reserve [5]. Thalidomide, as a palliative and antiemetic, has been marketized to treat during-pregnancy vomiting, but later withdrawn for its teratogenic effect [25]. In 1960, its immunomodulatory effect was exploited to deal with Behcet’s disease and erythema nodosum [26]. Currently, this drug is selected for refractory CD that fails first-line and second-line treatments [27, 28].

We speculate that thalidomide can repress TGF to inhibit follicular growth and decrease ovarian reserve. TGF-α acts to promote the proliferation and differentiation of germ cells. In vitro studies have exhibited that TGF-α is expressed in ovarian follicles and theca-interstitial cells and regulates follicular growth, degeneration and atresia [29]. In the primordial phase, TGF-α is highly expressed in the oocytes, and as the primordial follicles develop, its expression decreases, indicating that it mainly modulates the development of primordial follicles and oocytes [30].

Thalidomide can suppress the expression of TNF-α, IL-6, IL-8, as well as TGF-α and TGF-β [31]. TGF downregulation further inhibits follicular growth, thus decreasing ovarian reserve. Therefore, CD women, if willing to be fertilized or pregnant, should avoid use of thalidomide. If unavoidable, their ovarian reserve should be closely monitored during medication.

We next assessed the effect of CD duration, extent, behavior and surgery on ovarian reserve. The results showed that they decreased ovarian reserve, but this decrease was not statistically significant. Previous studies have presented that surgery may decline the fertility of patients with inflammatory bowel disease, which can be explained by the fact that pelvic surgery, especially ileum pouch-anal anastomosis (IPPA), may injure reproductive organs, mainly the ovaries and oviducts [32]. But we did not find out the association between surgery and decreased ovarian reserve. We suppose that CD-related abdominal surgery brings less injury to pelvic organs in CD patients. In addition, the low fertility in CD women is not just associated with decreased ovarian reserve, but also post-surgical adhesions [33]. In the present study, we just evaluated the effect of ovarian reserve on fertility.

This study focused on the ovarian reserve function of patients with CD during their reproductive years, to explore the difference in AMH level between them and healthy women at matched age, and to analyze possible risk factors. Despite above-mentioned inspiring results, the present study, as a retrospective study, had certain limitations. First of all, although we recorded the patient’s fertility status, we lacked the data of adverse pregnancy outcome, and did not analyze the fertility status base on disease and drugs. Secondly, the methodology of serum AMH assays is still evolving and not globally standardized. The blood samples from both groups were not frozen during the study period and analyzed together at the end of recruiting for standardized AMH assay and methodology, which may cause some data bias. Finally, we did not compare AMH levels before and after medication. Long-term prospective studies may provide data on CD effect on ovarian reserve function in future. But we believe that our findings in the present study can be used to improve the management of CD women.


The ovarian reserve in CD women of child-bearing age is lower than that in healthy controls. Age, disease activity and thalidomide use are risk factors of decreased ovarian reserve. Thalidomide should be avoided in the treatment of CD women desiring fertilization. To prevent age-related infertility, an active therapy should be administered to induce CD remission and reproductive health education is needed.

Availability of data and materials

The datasets used or analysed during the current study are available from the corresponding author on reasonable request.


  1. Duricova D, Burisch J, Jess T, Gower-Rousseau C, Lakatos PL, EpiCom E. Age-related differences in presentation and course of inflammatory bowel disease: an update on the population-based literature. J Crohns Colitis. 2014;8(11):1351–61.

    Article  Google Scholar 

  2. Mountifield R, Bampton P, Prosser R, Muller K, Andrews JM. Fear and fertility in inflammatory bowel disease: a mismatch of perception and reality affects family planning decisions. Inflamm Bowel Dis. 2009;15(5):720–5.

    Article  Google Scholar 

  3. Druvefors E, Landerholm K, Hammar U, Myrelid P, Andersson RE. Impaired fertility in women with inflammatory bowel disease: a National Cohort Study from Sweden. J Crohns Colitis. 2021;15(3):383–90.

    Article  Google Scholar 

  4. Clark-Snustad K, Butnariu M, Afzali A. Women's health and ulcerative colitis. Gastroenterol Clin N Am. 2020;49(4):769–89.

    Article  Google Scholar 

  5. Peng X, Zhi M, Wei M, Li TT, Zhang M, Zhang YQ, et al. Thalidomide results in diminished ovarian reserve in reproductive age female IBD patients. Medicine (Baltimore). 2017;96(21):e6540.

    Article  CAS  Google Scholar 

  6. Selinger CP, Eaden J, Selby W, Jones DB, Katelaris P, Chapman G, et al. Inflammatory bowel disease and pregnancy: lack of knowledge is associated with negative views. J Crohns Colitis. 2013;7(6):e206–13.

    Article  Google Scholar 

  7. Purewal S, Chapman S, Czuber-Dochan W, Selinger C, Steed H, Brookes MJ. Systematic review: the consequences of psychosocial effects of inflammatory bowel disease on patients' reproductive health. Aliment Pharmacol Ther. 2018;48(11-12):1202–12.

    Article  Google Scholar 

  8. Selinger CP, Ghorayeb J, Madill A. What factors might drive voluntary childlessness (VC) in women with IBD? Does IBD-specific pregnancy-related knowledge matter? J Crohns Colitis. 2016;10(10):1151–8.

    Article  Google Scholar 

  9. Leenhardt R, Riviere P, Papazian P, Nion-Larmurier I, Girard G, Laharie D, et al. Sexual health and fertility for individuals with inflammatory bowel disease. World J Gastroenterol. 2019;25(36):5423–33.

    Article  Google Scholar 

  10. Hammami MB, Mahadevan U. Men with inflammatory bowel disease: sexual function, fertility, medication safety, and prostate cancer. Am J Gastroenterol. 2020;115(4):526–34.

    Article  Google Scholar 

  11. Meduri G, Massin N, Guibourdenche J, Bachelot A, Fiori O, Kuttenn F, et al. Serum anti-Mullerian hormone expression in women with premature ovarian failure. Hum Reprod. 2007;22(1):117–23.

    Article  CAS  Google Scholar 

  12. Riggs RM, Duran EH, Baker MW, Kimble TD, Hobeika E, Yin L, et al. Assessment of ovarian reserve with anti-Mullerian hormone: a comparison of the predictive value of anti-Mullerian hormone, follicle-stimulating hormone, inhibin B, and age. Am J Obstet Gynecol. 2008;199(2):202 e201–8.

    Article  Google Scholar 

  13. Clowse ME, Harward L, Criscione-Schreiber L, Pisetsky D, Copland S. Anti-Mullerian hormone: a better marker of ovarian damage from cyclophosphamide. Arthritis Rheum. 2012;64(5):1305–10.

    Article  Google Scholar 

  14. Practice Committee of the American Society for Reproductive M. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2015;103(3):e9–e17.

    Article  Google Scholar 

  15. Marri SR, Ahn C, Buchman AL. Voluntary childlessness is increased in women with inflammatory bowel disease. Inflamm Bowel Dis. 2007;13(5):591–9.

    Article  Google Scholar 

  16. Mayberry JF, Weterman IT. European survey of fertility and pregnancy in women with Crohn's disease: a case control study by European collaborative group. Gut. 1986;27(7):821–5.

    Article  CAS  Google Scholar 

  17. Woolfson K, Cohen Z, McLeod RS. Crohn's disease and pregnancy. Dis Colon Rectum. 1990;33(10):869–73.

    Article  CAS  Google Scholar 

  18. Van Assche G, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vos M, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis. 2010;4(1):63–101.

    Article  Google Scholar 

  19. Wallace WH, Kelsey TW. Human ovarian reserve from conception to the menopause. PLoS One. 2010;5(1):e8772.

    Article  Google Scholar 

  20. Fonager K, Sorensen HT, Olsen J, Dahlerup JF, Rasmussen SN. Pregnancy outcome for women with Crohn's disease: a follow-up study based on linkage between national registries. Am J Gastroenterol. 1998;93(12):2426–30.

    Article  CAS  Google Scholar 

  21. Freour T, Miossec C, Bach-Ngohou K, Dejoie T, Flamant M, Maillard O, et al. Ovarian reserve in young women of reproductive age with Crohn's disease. Inflamm Bowel Dis. 2012;18(8):1515–22.

    Article  Google Scholar 

  22. Winger EE, Reed JL, Ashoush S, Ahuja S, El-Toukhy T, Taranissi M. Treatment with adalimumab (Humira) and intravenous immunoglobulin improves pregnancy rates in women undergoing IVF. Am J Reprod Immunol. 2009;61(2):113–20.

    Article  CAS  Google Scholar 

  23. Senates E, Colak Y, Erdem ED, Yesil A, Coskunpinar E, Sahin O, et al. Serum anti-Mullerian hormone levels are lower in reproductive-age women with Crohn's disease compared to healthy control women. J Crohns Colitis. 2013;7(2):e29–34.

    Article  Google Scholar 

  24. Moens A, van der Woude CJ, Julsgaard M, Humblet E, Sheridan J, Baumgart DC, et al. Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. Aliment Pharmacol Ther. 2020;51(1):129–38.

    Article  CAS  Google Scholar 

  25. Speirs AL. Thalidomide and congenital abnormalities. Lancet. 1962;1(7224):303–5.

    Article  CAS  Google Scholar 

  26. Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet. 2004;363(9423):1802–11.

    Article  CAS  Google Scholar 

  27. Vasiliauskas EA, Kam LY, Abreu-Martin MT, Hassard PV, Papadakis KA, Yang H, et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology. 1999;117(6):1278–87.

    Article  CAS  Google Scholar 

  28. Sabate JM, Villarejo J, Lemann M, Bonnet J, Allez M, Modigliani R. An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease. Aliment Pharmacol Ther. 2002;16(6):1117–24.

    Article  CAS  Google Scholar 

  29. Ozcakir HT, Giray SG, Ozbilgin MK, Uyar Y, Lacin S, Caglar H. Immunohistochemical detection of transforming growth factor-alpha, epidermal growth factor, and vascular endothelial growth factor expression in hyperstimulated rat ovary. Acta Obstet Gynecol Scand. 2005;84(9):887–93.

    Google Scholar 

  30. Qu J, Nisolle M, Donnez J. Expression of transforming growth factor-alpha, epidermal growth factor, and epidermal growth factor receptor in follicles of human ovarian tissue before and after cryopreservation. Fertil Steril. 2000;74(1):113–21.

    Article  CAS  Google Scholar 

  31. Sharma GT, Dubey PK, Kumar GS. Effects of IGF-1, TGF-alpha plus TGF-beta1 and bFGF on in vitro survival, growth and apoptosis in FSH-stimulated buffalo (Bubalis bubalus) preantral follicles. Growth Hormon IGF Res. 2010;20(4):319–25.

    Article  CAS  Google Scholar 

  32. van der Woude CJ, Ardizzone S, Bengtson MB, Fiorino G, Fraser G, Katsanos K, et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. 2015;9(2):107–24.

    Article  Google Scholar 

  33. Lee S, Crowe M, Seow CH, Kotze PG, Kaplan GG, Metcalfe A, et al. The impact of surgical therapies for inflammatory bowel disease on female fertility. Cochrane Database Syst Rev. 2019;7:CD012711.

    Google Scholar 

Download references


The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by grants form the National Natural Science Foundation of China (grant nos.91942303,81900490) and Li Jie-shou Intestinal Barrier Research Fund (grant nos. LJS-201908C).

Author information

Authors and Affiliations



Peng Xiang and Min Zhi were involved in study conception and design; Xiang Peng and Xiao-lan Li performed literature search and data collection; Xiang Peng and Jia-yin Yao performed data analysis; Peng Xiang, Jia-yin Yao were involved in drafting of the manuscript; Peng Xiang, Xiao-lan Li, Jia Yin Yao, Min Zhang, Pin-jin Hu, Min Zhi were involved in critical revision of the manuscript for important intellectual content; All authors have approved the final version of the manuscript.

Corresponding author

Correspondence to Min Zhi.

Ethics declarations

Ethics approval and consent to participate

The study was conducted in compliance with all national and international ethical standards for research with humans. This clinical trial was approved by the Ethics Committee of the Sixth Affiliated Hospital, Sun Yat-sen University (2017ZSLYEC-077). Informed consent was exempted because it was a retrospective study.

Consent for publication

All authors consent to publish.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xiang, P., Yao, Jy., Li, Xl. et al. Clinical characteristics and risk factors of ovarian reserve decreases in women with Crohn’s disease: a case-control study. J Ovarian Res 16, 34 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • Crohn’s disease
  • Anti-Müllerian hormone
  • Ovarian reserve